

## Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China

- The new investments will include three 1,000L GMP trains with an overall 12m<sup>3</sup> of reactor volume, including new development and GMP laboratories with capabilities to manufacture small scale batches of highly potent APIs (HPAPIs)
- Expanded capacity in Nansha will allow for mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
- Capabilities add to Lonza's integrated global manufacturing network, which maintains rigorous quality and regulatory standards around the world

### Quote from Jan Vertommen, Senior Director, Commercial Development, Lonza:

“Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with. These companies need cost-effective, seamless ways to move small molecule compounds from early-phase to commercial according to global quality and regulatory standards, and these expanded facilities at our Nansha site are designed to help them to do so.”

### Quote from Gordon Bates, President, Division Small Molecules, Lonza:

“Global pharma and biotech companies are increasingly looking to China, both for development and manufacturing of global products and in some cases for greater access to clinical trials conducted in China. With these expanded capabilities at our Nansha site, we aim to support the next generation of innovative and life-saving drug development with our customers around the world.”

**Basel, Switzerland, 28 June 2021** – Lonza today announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million, will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza's global quality and regulatory standards.

The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. The additional GMP laboratories will be able to develop and manufacture highly potent API (HPAPI) under GMP standards.

Lonza's Nansha site is fully integrated within the company's global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. The Lonza team also contains regulatory specialists with experience working with Chinese regulators throughout the drug development and scale-up process. Approximately 250 employees work at Lonza's Nansha site; this expansion is expected to create around 70 new positions.

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022.

Visit <https://pharma.lonza.com/about/locations/nansha-china> for more information.

### **About Lonza**

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at [www.lonza.com](http://www.lonza.com).

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

### **Lonza Contact Details**

#### **Dr. Martina Ribar Hesticová**

Trade Media Lead

Lonza Group Ltd

Tel +41 61 316 8982

[martina.ribarhesticova@lonza.com](mailto:martina.ribarhesticova@lonza.com)

#### **Dirk Oehlers**

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

[dirk.oehlers@lonza.com](mailto:dirk.oehlers@lonza.com)

**Additional Information and Disclaimer**

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.